Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$0.12
EPS est.
$0.23
EPS surprise
-48.50%
1-day move
+16.26%
TG Therapeutics reported an EPS of $0.12, which was below expectations, resulting in a significant stock increase of 16.26%. This reaction may indicate investor optimism despite the earnings miss. The lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.12 | N/A | -48.50% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
TG Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs with novel treatment options.
Last quarter
In the last quarter, TG Therapeutics reported an EPS of $0.14, which was significantly below the estimated $0.35, resulting in a 60.45% surprise to the downside. The stock reacted positively the next day, gaining 4.18%.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
+77.37%
Avg 1-day reaction
-2.53%
Overall, expectations are mixed as the company has a history of both beating and missing EPS estimates. Investors will be keen to see if the company can turn around its recent performance.
Bull case
If TG Therapeutics can deliver strong clinical trial results and exceed EPS expectations, it could signal a turnaround and boost investor confidence.
Bear case
On the other hand, if the company continues to miss EPS estimates and fails to provide clear guidance on its pipeline, it could lead to further declines in stock price.
The print will turn on these.
Q1
What will the EPS be this quarter, and how does it compare to analyst expectations?
Given the company's recent history of missing EPS estimates, this figure will be crucial in determining market sentiment.
Q2
What updates can management provide on the progress of clinical trials?
Investors are particularly interested in the success of clinical trials, as this can significantly impact the company's future growth and stock performance.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for TG Therapeutics to surprise on the upside with its clinical trial results, which have shown promise in preliminary stages.
Supporting evidence
The company's recent focus on operational improvements may yield better-than-expected results.
Options pricing suggests a lower expected move compared to historical averages, indicating potential for a surprise.
The positive reaction to the last quarter's results, despite a miss, shows underlying investor interest.
Key risk
If clinical trial results exceed expectations, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as the company seeks to regain investor confidence after a series of disappointing earnings.
Bull confirmed if
A positive EPS surprise of at least 15% would confirm the bull case and suggest improving operational performance.
Bear confirmed if
An EPS miss of more than 20% would reinforce the bear case and raise concerns about the company's future prospects.
What the market is pricing for the move.
Implied Move
±9.48%
Historical Avg
±11.2%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±10.3% while TGTX has averaged ±11.2% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.8%
30d HV
41.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If TG Therapeutics beats expectations, history suggests the stock could rise by an average of 10.28%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.
Miss
A miss could lead to a decline of around 4.05%, reflecting ongoing concerns about the company's performance.
The lines on the call that would change the story.